Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword?
Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword?
复制标题
DOI：
10.1093/eurheartj/ehn384
复制
发表时间：
2008-10-01
影响因子：
39.3
通讯作者：
Lishner, Michael
中科院分区：
文献类型：
--
作者：
Pereg, David;Lishner, Michael
近年来，针对血管内皮生长因子(VEGF)的新型人源化单抗贝伐珠单抗已显示出良好的临床前和临床抗癌活性。然而，也有人担心使用它可能会增加动脉血栓栓塞症的风险，特别是在既有心血管疾病的患者中。另一方面，贝伐单抗治疗与出血风险增加有关，联合应用阿司匹林和氯吡格雷等抗血小板药物可能会增加出血风险。在这篇文章中，我们介绍了可用的数据，确定了争议和未解决的问题，并提出了关于贝伐单抗治疗癌症心血管疾病患者的解决方案。
Recently, bevacizumab, the novel humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF), has shown promising preclinical and clinical anti-cancer activity. However, concerns have been raised regarding a possible increased risk for arterial thrombo-embolic events associated with its administration, especially in patients with pre-existing cardiovascular disease. On the other hand, bevacizumab treatment is associated with an increased bleeding risk that may be augmented by the co-administration of anti-platelet drugs such as aspirin and clopidogrel. In this paper, we present the available data, identify controversies and unresolved issues, and suggest solutions regarding the administration of bevacizumab to cancer patients with cardiovascular disease.